Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Trump Buys SpaceX Shares After Record IPO 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Ampol Profit Surges as Refining Margins Hit Record Highs 
 To Contact The Firm - EconoTimes)
Add as a preferred source on Google
STEVENSON, Md., May 02, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Illinois on behalf of purchasers of Akorn, Inc. (Nasdaq:AKRX) (“Akorn” or the “Company”) securities during the period between March 1, 2017 through February 26, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 7, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Akorn securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Akorn’s failure to comply with the U.S. Food and Drug Administration (“FDA”) data integrity requirements would jeopardize Fresenius SE & Co. KGaA’s acquisition of Akorn, and the Company lacked effective internal controls over financial reporting.
According to the complaint, following a February 28, 2018 announcement that the Company was conducting an investigation into alleged breaches of FDA data integrity requirements, the value of Akorn shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Akorn securities purchased on or after March 1, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]
